United Therapeutics Corporation Reports First Quarter 2026 Financial Results

AI Briefing

• – Total revenues decreased 2% year-over-year to $781.5M, down from $794.4M in Q1 2025.
• – Clinical success continued with positive results from ADVANCE study.
• – Q1 2026 results reflect challenges in a competitive market.